Status: Recruiting
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
Participants needed: 201
Trial details
Phase: Phase 3Age: 12-17Biological sex: AllType: InterventionalSponsor: Guangdong Hengrui Pharmaceutical Co., LtdUpdated: Apr 7, 2026Locations: 2
Eligibility criteria
Male or female ≥12 to ≤17 years of age at time of screening visit, body weight ≥... [+6]
Has other active skin diseases (e.g., psoriasis or systemic lupus erythematosus)... [+19]